Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.55 |
| ▸ | SPR | P35270 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.52 |
| ▸ | HTR2C | P28335 | 3/20 | 0.52 |
| ▸ | NAMPT | P43490 | 5/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27917812 | 0.87 | HTR2A (0.58) | HTR2ASPRKCNH2HTR2CDRD2 | |
| SCHEMBL14413086 | 0.84 | HTR2A (0.55) | HTR2ASPRKCNH2HTR2CDRD2 | |
| SCHEMBL18711351 | 0.83 | RBP4 (0.50) | HTR2ASPRKCNH2HTR2CACHE | |
| SCHEMBL14242442 | 0.83 | BLM (0.55) | HTR2ASPRKCNH2HTR2CNAMPT | |
| SCHEMBL14227531 | 0.83 | HTR2A (0.51) | HTR2ASPRKCNH2HTR2CDRD2 | |
| SCHEMBL16631997 | 0.81 | NAMPT (0.53) | HTR2ANAMPTTXNRD1CNR2AKT1 | |
| SCHEMBL15231711 | 0.81 | HTR2A (0.48) | HTR2AKCNH2HTR2CNAMPTTXNRD1 | |
| SCHEMBL13947675 | 0.80 | GPR119 (0.59) | NAMPTKMT2A | |
| SCHEMBL13873196 | 0.80 | LMNA (0.52) | HTR2ASPRKCNH2HTR2CDRD2 | |
| SCHEMBL5704984 | 0.80 | HTR2A (0.62) | HTR2ASPRKCNH2HTR2CNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3356345-B1 | HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2023-11-08 | — | — | EP | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-9315454-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | HTR2A 1410/4885SPR 1/4885KCNH2 2751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.